ArticleBMC pharmacology & toxicology2025

Efficacy and safety of a B-cell-driven rituximab regimen for the treatment of refractory idiopathic membranous nephropathy.

Kaiqi Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.